Aspirin use and risk of colorectal cancer according to BRAF mutation status.

ABSTRACT:

Importance

Aspirin use reduces the risk of colorectal carcinoma. Experimental evidence implicates a role of RAF kinases in up-regulation of prostaglandin-endoperoxide synthase 2 (PTGS2, cyclooxygenase 2), suggesting that BRAF-mutant colonic cells might be less sensitive to the antitumor effects of aspirin than BRAF-wild-type neoplastic cells.

Objective

To examine whether the association of aspirin intake with colorectal cancer risk differs according to status of tumor BRAF oncogene mutation.

Design and setting

We collected biennial questionnaire data on aspirin use and followed up participants in the Nurses' Health Study (from 1980) and the Health Professionals Follow-up Study (from 1986) until July 1, 2006, for cancer incidence and until January 1, 2012, for cancer m

SUBMITTER: Nishihara R 

PROVIDER: S-EPMC3743040 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature